New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:51 EDTAZN, ISRG, SNDK, AKAM, CMGOptions with increasing implied volatility: AKAM ISRG CMG SNDK AZN
News For AKAM;ISRG;CMG;SNDK;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 14, 2014
14:12 EDTAKAMAkamai calls active
Subscribe for More Information
11:27 EDTAKAMAkamai hits highs of day amid takeover speculation
The move higher in shares of Akamai (AKAM) is being attributed to takeover speculation. The suitor rumored to be interested is Alibaba (BABA). Shares of Akamai are at highs of the day, up 3% to $62.00.
07:14 EDTAZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
10:01 EDTSNDKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
05:32 EDTSNDKSanDisk upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded SanDisk to Buy saying the weakening in the yen will likely be a positive for margins in 2015. Goldman raised its price target for shares to $106 from $87.
November 12, 2014
11:17 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
12:09 EDTAKAMRackspace soars after Q3 results top estimates, $500M share buyback plan
Subscribe for More Information
10:00 EDTAKAMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTAKAMAkamai initiated with an Outperform at Macquarie
Subscribe for More Information
November 10, 2014
15:55 EDTSNDKNeedham to hold a conference
Subscribe for More Information
10:30 EDTAKAMFireEye advances after JPMorgan adds to Focus List
Subscribe for More Information
07:57 EDTISRGIntuitive Surgical survey positive on hernia opportunity, says JPMorgan
JPMorgan said its survey of 25 U.S.-based general surgeons who have used da Vinci for hernia procedures yielded positive outlook on the hernia opportunity for Intuitive Surgical. The firm says the complexity of the robot does not appear to be an issue. It keeps an Overweight rating on Intuitive with a $550 price target.
07:30 EDTAKAMFireEye added to Focus List, Akamai removed at JPMorgan
Subscribe for More Information
07:23 EDTSNDKRBC Capital to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use